What Inozyme Pharma, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Winton Matthew | COO | Jul 01 | Tender Offer · U | −21,743 | $4.00 | −$87K | 0 |
| Hopfner Robert Lorne | Director | Jul 01 | Tender Offer · U | −1,571,741 | $4.00 | −$6.29M | 0 |
| Hopfner Robert Lorne | Director | Jul 01 | Tender Offer · U | −2,923,110 | $4.00 | −$11.7M | 0 |
| Subramanian Sanjay | SVP, CFO & Head of BD | Jul 01 | Tender Offer · U | −39,701 | $4.00 | −$159K | 0 |
| Treco Douglas A | CEO & Chairman | Jul 01 | Tender Offer · U | −43,861 | $4.00 | −$175K | 0 |
| Bolte Axel | Director | Jul 01 | Tender Offer · U | −423,926 | $4.00 | −$1.7M | 0 |
| Winton Matthew | COO | Jun 25 | Grant / award · A | +14,355 | $0.74 | +$10.6K | 21,743 |
| Subramanian Sanjay | SVP, CFO & Head of BD | Jun 25 | Grant / award · A | +6,813 | $0.74 | +$5.04K | 39,701 |
| Treco Douglas A | CEO & Chairman | Jun 25 | Grant / award · A | +2,815 | $0.74 | +$2.08K | 43,861 |
| Bolte Axel | Director | May 15 | Exercise / conversion · M | +4,407 | $0.98 | +$4.32K | 423,926 |
| Bolte Axel | Director | May 15 | Exercise / conversion · M | +152,823 | $0.98 | +$150K | 419,519 |
| Treco Douglas A | CEO & Chairman | Apr 02 | Open-market sale · S | −8,819 | $0.89 | −$7.85K | 41,046 |
| Treco Douglas A | CEO & Chairman | Apr 01 | Exercise / conversion · M | +25,000 | — | — | 49,865 |
| Winton Matthew | COO | Mar 31 | Grant / award · A | +2,490 | $0.77 | +$1.92K | 7,388 |
| Subramanian Sanjay | SVP, CFO & Head of BD | Mar 31 | Grant / award · A | +2,490 | $0.77 | +$1.92K | 32,888 |
| Winton Matthew | COO | Sep 30 | Grant / award · A | +1,710 | $4.45 | +$7.61K | 4,898 |
| Treco Douglas A | CEO | Sep 30 | Grant / award · A | +1,710 | $4.45 | +$7.61K | 22,375 |
| Treco Douglas A | CEO | Apr 02 | Open-market sale · S | −7,523 | $6.94 | −$52.2K | 20,665 |
| Treco Douglas A | CEO | Apr 01 | Exercise / conversion · M | +25,000 | — | — | 28,188 |
| Winton Matthew | COO | Mar 28 | Grant / award · A | +3,188 | $3.33 | +$10.6K | 3,188 |
Loading...
